Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury
Critical Care2010Vol. 14(1), pp. R9–R9
Citations Over TimeTop 10% of 2010 papers
Philipp Kümpers, Carsten Hafer, Alexander Lukasz, Ralf Lichtinghagen, Korbinian Brand, Danilo Fliser, Robert Faulhaber‐Walter, Jan T. Kielstein
Abstract
This is the first prospective evaluation of serum NGAL as an outcome-specific biomarker in critically ill patients at initiation of RRT. The results from this study indicate that serum NGAL is as an independent predictor of 28-day mortality in ICU patients with dialysis-dependent AKI.
Related Papers
- → Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy(2020)97 cited
- → Renal replacement therapy in the pediatric cardiac intensive care unit(2019)7 cited
- → Renal Replacement Therapy in Acute Kidney Injury: Indication, Proper Initiation, and Prescription(2012)
- → The effect of renal replacement therapy timing on the outcome of acute kidney injury in critically ill patients(2019)
- → POS-840 Acute kidney injury in critically ill COVID- 19 infected patients requiring renal replacement therapy(2022)